Implications of pharmacogenetics in every-day practice;Bedeutung der pharmakogenetik für die tägliche praxis

Internist

Volumn 46, Issue 11, 2005, Pages 1270-1277

  Gerloff, T ^a   Roots, I ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Drug metabolizing; Drug transporters; Pharmacogenetics; Pharmacology; Polymorphisms

Indexed keywords

AMITRIPTYLINE; AROMATASE; CLOMIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; DRUG METABOLIZING ENZYME; IMIPRAMINE; MAPROTILINE; MIANSERIN; NORTRIPTYLINE; PAROXETINE; THIOPURINE METHYLTRANSFERASE; TRIMIPRAMINE; VENLAFAXINE;

CLINICAL PRACTICE; DRUG RESPONSE; ENZYME DEFICIENCY; HEREDITY; MOLECULAR GENETICS; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; GENETIC SCREENING; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES; VARIATION (GENETICS);

EID: 28744435934     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1489-3     Document Type: Review

References (23)

1. Redfern WS, Wakefield ID, Prior H, Pollard CE, Hammond TG, Valentin JP (2002) Safety pharmacology - a progressive approach. Fundam Clin Pharmacol 16: 161-173
2. Brockmöller J, Kirchheiner J, Meisel C, Roots I (2000) Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1: 125-151
3. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M (2001) Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole and rabeprazole), amoxycillin and clarithromycin. Digest Liver Dis 33: 671-675
4. Furuta T, Shirai N, Takashima M et al. (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69: 158-168
5. Kirchheiner J, Brockmöller J (2005) Clinical consequences of cytochromes P450 2C9 polymorphisms. Clin Pharmacol Ther 77: 1-16
6. Kirchheiner J, Nickchen K, Bauer M, Licinio J, Wong ML, Roots I, Brockmöller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9: 442-473
7. McLeod HL, Miller DR, Evans WE (1993) Azathioprine-induced Myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341: 1151
8. Yates CR, Krynetski EY, Loennechen T et al. (1997) Molecular diagnosis ofthiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126: 608-614
9. Schaeffeler E, Fischer C, Brockmeier D et al. (2004) Comprehensive analysis ofthiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14: 407-417
10. Hoffmeyer S, Burk O, von Richter O et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478
11. Johne A, Köpke K, Gerloff T et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72: 584-594
12. Fellay J, Marzolini C, Meaden ER et al. (2002) Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359: 30-36
13. Nishizato Y, Ieiri I, Suzuki H et al. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73: 554-565
14. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1 b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75: 415-421
15. Tachibana-Iimori R, Tabara Y, Kusuhara H et al. (2004) Drug Metab Pharmacokinet 19: 375-380
16. 2 adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345: 1213-1214
17. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350: 995-999
18. 2-adrenocep-tor polymorphism. Thorax 55: 762-767
19. 2-agonist therapy in asthma. Eur Respir J 11: 589-593
20. Israel E, Chinchilli VM, Ford JG et al.; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-overtrial. Lancet 364: 1505-1512
21. McLeod HL, Siva C (2002) The thiopurine S.methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3: 89-98
22. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG (2004) Availability of pharmacogenomics-based prescribing information in currently approved drugs. Pharmacogenomics J 4: 354-358
23. Robertson JA, Brody B, Buchanan A, Kahn J, McPherson E (2002) Pharmacogenetic challenges for the health care system. Health Affairs 21: 155-167